Crinetics Pharmaceuticals, Inc.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.7M
- Net income
- -$465.3M
- Total assets
- $1.1B
- Market cap
- $3.5B
- Gross margin
- 86.0%
- Operating margin
- -6714.8%
- Net margin
- -6046.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $7.7M
- Cost of revenue
- $1.1M
- Gross profit
- $6.6M
- Operating expenses
- $523.4M
- Operating income
- -$516.8M
- Income tax
- $180.0K
- Net income
- -$465.3M
- EPS (basic)
- $-4.95
- EPS (diluted)
- $-4.95
Balance sheet
- Total assets
- $1.1B
- Current assets
- $1.0B
- Total liabilities
- $134.2M
- Current liabilities
- $85.1M
- Shareholders’ equity
- $992.1M
Cash flow
- Operating cash flow
- -$377.9M
- Investing cash flow
- $173.9M
- Financing cash flow
- $40.6M
- Net cash flow
- -$163.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.5B
- EPS (diluted)
- $-4.95
- Shares outstanding
- 103.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 18, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $465.3M in FY2025.
- Revenue grew 10739% from FY2020 to FY2025.
- Gross margin of 86.0%, net margin -6046.2%.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Crinetics Pharmaceuticals, Inc..
Write a review
News about Crinetics Pharmaceuticals, Inc.
News & sentiment via Polygon.io
